Viemed Healthcare (VMD) AI Stock Analysis

• Market Cap: $260.80M
• Dividend Yield: N/A
• Average Volume (3M): 153.88K
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.79
• Revenue Growth: 18.90%
• EPS Growth: 29.22%
• Country: US
• Employees: 1,222
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.09
• Shares Outstanding: 38,017,906
• 10 Day Avg. Volume: 138,759
• 30 Day Avg. Volume: 153,881
• PEG Ratio: 3.72
• Price to Book (P/B): 2.37
• Price to Sales (P/S): 1.39
• P/FCF Ratio: 235.82
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 1.14
• Enterprise Value/Gross Profit: 1.97
• Enterprise Value/Ebitda: 6.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.43
• Revenue Forecast (FY): $273.55M

• Rating: 76 Outperform
• Price Target: $8.00 ▲(16.79% Upside)

Viemed Healthcare's strong financial performance, positive technical indicators, and upbeat earnings call contribute to a favorable stock score. The company's robust revenue growth and strategic expansions are significant strengths, though challenges in cash flow conversion and valuation concerns slightly temper the outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market expansion and product adoption, supporting long-term business sustainability and competitive positioning.

Business Diversification

Diversification into new segments like sleep and maternal health reduces dependency on a single revenue source, enhancing resilience against market fluctuations.

Cash Flow Generation

Strong cash flow generation provides financial flexibility for strategic investments and supports sustainable growth initiatives.

Negative Factors

Gross Margin Pressure

Pressure on gross margins from lower-margin services could impact profitability, necessitating efficiency improvements to maintain financial health.

Narrowed Revenue Guidance

Narrowed revenue guidance reflects potential challenges in achieving growth targets, which could affect investor confidence and strategic planning.

Free Cash Flow Conversion

Challenges in converting earnings to free cash flow may limit the company's ability to fund new projects and respond to market opportunities.

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare (VMD) is a prominent provider of home healthcare services, specializing in the treatment of patients with chronic respiratory conditions. The company operates primarily in the home medical equipment sector, offering a range of products and services including respiratory therapy, equipment rental and sales, and patient monitoring solutions. Viemed is committed to improving patient outcomes through innovative healthcare solutions delivered in the comfort of patients' homes.

How the Company Makes Money

Viemed Healthcare generates revenue primarily through the provision of home healthcare services and the rental and sale of durable medical equipment (DME) to patients with chronic respiratory diseases. The company’s revenue model includes reimbursement from Medicare and private insurers for the services provided and equipment delivered. Key revenue streams consist of monthly rental fees for equipment, such as ventilators and CPAP machines, as well as reimbursement for in-home therapy services. Significant partnerships with healthcare payers and managed care organizations facilitate access to a larger patient base, thereby enhancing the company's earnings potential.

Viemed Healthcare Financial Statement Overview

Summary

Viemed Healthcare demonstrates solid financial health with strong revenue growth and profitability. The balance sheet is robust with low leverage, enhancing financial stability. However, cash flow management presents challenges, particularly in converting earnings to free cash flow, which may impact future growth opportunities.

Income Statement

Viemed Healthcare shows a consistent revenue growth trend, with a TTM revenue growth rate of 5.78%. The gross profit margin remains strong at 58.19%, although it has slightly decreased from previous years. The net profit margin is stable at 5.80%, indicating profitability. However, the EBIT and EBITDA margins show moderate levels, suggesting room for operational efficiency improvements.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.05, indicating low leverage and financial stability. The return on equity is healthy at 10.53%, reflecting effective use of equity. The equity ratio is strong, suggesting a robust capital structure with a significant portion of assets financed by equity.

Cash Flow

Operating cash flow is strong, with a coverage ratio of 1.15, indicating good cash generation relative to net income. However, the free cash flow growth rate is negative, which could be a concern for future investments. The free cash flow to net income ratio is negative, suggesting challenges in converting net income into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	254.79M	224.26M	183.01M	138.83M	117.06M	131.31M
Gross Profit	147.14M	133.20M	112.78M	84.68M	73.41M	80.11M
EBITDA	48.44M	42.31M	36.68M	24.82M	24.13M	36.45M
Net Income	13.61M	11.27M	10.24M	6.22M	9.13M	31.53M
Balance Sheet
Total Assets	202.36M	177.07M	154.90M	117.04M	117.96M	112.56M
Cash, Cash Equivalents and Short-Term Investments	11.12M	17.54M	12.84M	16.91M	28.41M	30.98M
Total Debt	24.70M	6.87M	10.32M	694.00K	6.52M	11.13M
Total Liabilities	66.86M	43.77M	41.00M	19.95M	23.14M	30.87M
Stockholders Equity	133.61M	131.39M	113.89M	97.09M	94.82M	81.69M
Cash Flow
Free Cash Flow	5.38M	1.32M	19.12M	4.85M	2.75M	22.07M
Operating Cash Flow	48.46M	39.09M	45.21M	27.75M	22.49M	35.11M
Investing Cash Flow	-51.75M	-30.70M	-52.11M	-23.98M	-19.75M	-8.41M
Financing Cash Flow	3.07M	-3.69M	2.83M	-15.27M	-5.32M	-9.07M

Viemed Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Positive. The current price of 6.85 is above the 20-day moving average (MA) of 6.47, above the 50-day MA of 6.68, and below the 200-day MA of 6.90, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.37 is Neutral, neither overbought nor oversold. The STOCH value of 93.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VMD.

Viemed Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	76 Outperform	$260.80M	20.75	10.53%	―	18.90%	29.22%
TCMD	75 Outperform	$571.12M	33.01	8.80%	―	9.28%	21.00%
BVS	64 Neutral	$613.28M	65.98	4.97%	―	1.58%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INGN	48 Neutral	$192.21M	―	-13.27%	―	4.68%	55.37%
SENS	45 Neutral	$245.97M	―	-129.29%	―	31.94%	36.59%
OM	42 Neutral	$78.51M	―	-92.33%	―	4.65%	68.71%

Viemed Healthcare Corporate Events

Viemed Healthcare Amends Credit Agreement with Lenders

On November 7, 2025, Viemed Healthcare, Inc. announced a Third Amendment to its Credit Agreement, extending the expiration date of the Borrower’s delayed draw term loan commitment to November 29, 2026. This amendment, involving Regions Bank and other lenders, includes technical changes and is part of Viemed’s ongoing financial strategy. The company also released an Investor Deck Presentation for use in discussions with investors and analysts, highlighting its financial performance and growth strategy.

The most recent analyst rating on (VMD) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.

Viemed Healthcare Reports Record Third Quarter 2025

Viemed Healthcare, Inc. is a U.S.-based in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services, including non-invasive ventilators and sleep therapy. The company focuses on delivering effective in-home treatment through a combination of clinical expertise and advanced technology.

Viemed Healthcare Reports Record Q3 2025 Revenues and Strategic Growth

Viemed Healthcare reported record net revenues of $71.9 million for the third quarter of 2025, marking a 24% increase from the previous year. The company’s strategic acquisition of Lehan’s Medical Equipment and completion of its share repurchase program have contributed to its financial growth, enhancing market presence and diversifying service capabilities. The company also updated its full-year 2025 financial guidance, reflecting increased visibility into the year’s remainder, with expectations for net revenue and adjusted EBITDA slightly adjusted. These developments underscore Viemed’s commitment to shareholder value and patient outcomes.

The most recent analyst rating on (VMD) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.

Viemed Healthcare Completes Share Repurchase Program

On September 23, 2025, Viemed Healthcare announced the completion of its share repurchase program, having repurchased 1,976,441 common shares for approximately $13.2 million. This move underscores Viemed’s confidence in its long-term prospects and commitment to enhancing shareholder value, supported by a strong balance sheet and increasing free cash flow.

The most recent analyst rating on (VMD) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.

Viemed Healthcare’s Earnings Call Highlights Robust Growth

Viemed Healthcare’s recent earnings call painted a picture of robust growth and strategic advancement, with the company showcasing significant achievements in its core operations. The sentiment was overwhelmingly positive, driven by strong performances in key areas such as ventilation and sleep therapy, alongside strategic acquisitions that have bolstered the company’s future outlook. Despite minor setbacks in the staffing sector and a slight dip in gross margins, Viemed’s overall trajectory remains promising, underscoring its solid positioning for continued success.

Viemed Healthcare Reports Strong Q2 2025 Growth

Viemed Healthcare, Inc. is a U.S.-based in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services, including non-invasive ventilators and sleep therapy. The company focuses on delivering efficient in-home treatment through high-touch and high-tech services.